Marco Maruzzo
Istituto Oncologico Veneto · 388 works · 3,771 citations · h-index 31
Top works
- ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
- Treatment of Estrogen Receptor-Positive Breast Cancer
- Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
- A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience.
- Extra-nodal extension of sentinel lymph node metastasis is a marker of poor prognosis in breast cancer patients: A systematic review and an exploratory meta-analysis
- Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
- Pazopanib as first line treatment for solitary fibrous tumours: the Royal Marsden Hospital experience
- Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers
- Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
- Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa)
- Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER.
- Malignant Hypercalcemia
- First-Line PAzopanib in NOn–clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study
- Extranodal Extension of Nodal Metastases Is a Poor Prognostic Indicator in Gastric Cancer: a Systematic Review and Meta-analysis
- Systemic treatment options for epithelioid haemangioendothelioma: the Royal Marsden Hospital experience.
- Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study
- Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
- Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma
- Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
- Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis